+

WO2003011327A3 - Secretin for the treatment of asthma - Google Patents

Secretin for the treatment of asthma Download PDF

Info

Publication number
WO2003011327A3
WO2003011327A3 PCT/GB2002/003433 GB0203433W WO03011327A3 WO 2003011327 A3 WO2003011327 A3 WO 2003011327A3 GB 0203433 W GB0203433 W GB 0203433W WO 03011327 A3 WO03011327 A3 WO 03011327A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretin
tissue
asthma
treatment
patient
Prior art date
Application number
PCT/GB2002/003433
Other languages
French (fr)
Other versions
WO2003011327A2 (en
Inventor
Richard Jon Davis
Kenneth Clark
Original Assignee
Pharmagene Lab Ltd
Richard Jon Davis
Kenneth Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagene Lab Ltd, Richard Jon Davis, Kenneth Clark filed Critical Pharmagene Lab Ltd
Priority to US10/484,922 priority Critical patent/US20040241154A1/en
Priority to EP02749066A priority patent/EP1411972A2/en
Publication of WO2003011327A2 publication Critical patent/WO2003011327A2/en
Publication of WO2003011327A3 publication Critical patent/WO2003011327A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is based on the finding that the secretin receptor is expressed in tissues present in the distal lung of humans. In patient with asthma, levels of the receptor are elevated compared to normal tissue. Treatment of tissue by secretin stimulates the movement of negative ions in the tissue. Addition of secretin to human bronchial tissue in vitro stimulates bronchorelaxation. The invention provides methods of treatment of asthma in a patient by administering to said patient an effective amount of an agent which triggers anion efflux and bronchorelaxation in respiratory tissue via the activation of a secretin receptor.
PCT/GB2002/003433 2001-07-27 2002-07-26 Secretin for the treatment of asthma WO2003011327A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/484,922 US20040241154A1 (en) 2001-07-27 2002-07-26 Secretin for the treatment of asthma
EP02749066A EP1411972A2 (en) 2001-07-27 2002-07-26 Secretin for the treatment of asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0118383.9 2001-07-27
GBGB0118383.9A GB0118383D0 (en) 2001-07-27 2001-07-27 Therapeutic methods

Publications (2)

Publication Number Publication Date
WO2003011327A2 WO2003011327A2 (en) 2003-02-13
WO2003011327A3 true WO2003011327A3 (en) 2003-11-06

Family

ID=9919335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/003433 WO2003011327A2 (en) 2001-07-27 2002-07-26 Secretin for the treatment of asthma

Country Status (4)

Country Link
US (1) US20040241154A1 (en)
EP (1) EP1411972A2 (en)
GB (1) GB0118383D0 (en)
WO (1) WO2003011327A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US7409766B2 (en) * 2004-07-08 2008-08-12 Mentor Group Llc Folding tool with blade locking mechanism
US20070169351A1 (en) * 2006-01-25 2007-07-26 Mentor Group Llc Folding tool with lockback mechanism
WO2008052143A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
JP5595041B2 (en) 2006-10-25 2014-09-24 リバルシオ コーポレイション Methods of therapeutic treatment of eyes and other human tissues using oxygen enriched solutions
US8784897B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
JP5491185B2 (en) 2006-10-25 2014-05-14 リバルシオ コーポレイション Wound care and treatment methods
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
MX2010004563A (en) * 2007-10-25 2010-07-28 Revalesio Corp Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction.
JP5901291B2 (en) 2008-05-01 2016-04-06 リバルシオ コーポレイション Compositions and methods for treating digestive disorders
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
MX2012012971A (en) 2010-05-07 2013-02-07 Revalesio Corp Compositions and methods for enhancing physiological performance and recovery time.
EA201300228A1 (en) 2010-08-12 2013-06-28 Ревалезио Корпорейшн COMPOSITIONS AND METHODS OF TREATMENT OF TAUPATIA

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833722A (en) * 1971-03-16 1974-09-03 D Graybill Method for controlling allergies
US5428015A (en) * 1990-06-26 1995-06-27 Sana Kagaku Kenkyusho Co., Ltd. Vasoactive intestinal polypeptide analogues and use thereof
WO1995027496A1 (en) * 1994-04-07 1995-10-19 Proteinix Company Vasoactive intestinal polypeptide
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833722A (en) * 1971-03-16 1974-09-03 D Graybill Method for controlling allergies
US5428015A (en) * 1990-06-26 1995-06-27 Sana Kagaku Kenkyusho Co., Ltd. Vasoactive intestinal polypeptide analogues and use thereof
WO1995027496A1 (en) * 1994-04-07 1995-10-19 Proteinix Company Vasoactive intestinal polypeptide
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism

Also Published As

Publication number Publication date
US20040241154A1 (en) 2004-12-02
EP1411972A2 (en) 2004-04-28
GB0118383D0 (en) 2001-09-19
WO2003011327A2 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
WO2003011327A3 (en) Secretin for the treatment of asthma
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
WO2003032815A3 (en) Medical device for delivering patches
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
BRPI0412526A (en) compound, use of a compound, pharmaceutical composition, pharmaceutical aerosol formulation, and method for treating a human or animal patient with an anti-inflammatory and / or allergic condition
WO2007049017A3 (en) Agents that bind a target in pulmonary tissue for treating respiratory diseases
WO2007089454A3 (en) Methods for enhancing skin treatments
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2005078124A3 (en) Diagnostic marker for cancer
EP2322217A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
WO2003041686A3 (en) Improved therapy for topical diseases
BR0209658A (en) 4-Amino-5-phenyl-7-1-cyclobutyl-pyrrolo [2,3-d] pyrimidine derivatives
TR200001891T2 (en) ASPB28- Human insulin and its use.
WO2006100677A3 (en) Device and method for pupil size modulation
CA2474479A1 (en) Composition for inhalation
WO2005041921A3 (en) Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
MXPA02012755A (en) Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd).
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions
NO20054767L (en) Compositions comprising apomorphine for lung inhalation
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
SI1407776T1 (en) A pharmaceutical colloidal preparation comprising hyaluronic acid biopolymers useful in the treatment of respiratory diseases
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
NZ597657A (en) Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002749066

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002749066

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10484922

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002749066

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载